COVID-19 Primary care Platform for Early treatment and Recovery (COPPER) Study: an open-label randomized controlled trial

Phase 4

Completed

• Conditions: Corona; COVID-19; 10047438

• Registration Number: NL-OMON50987
• Lead Sponsor: General Practitioners Research Institute

Brief Summary

Trial ended prematurely

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 2000

Inclusion Criteria

- Age *18 years
- A positive test for SARS-CoV-2
- A GP consultation for deteriorating COVID-19 symptoms
- Exercise-induced desaturation, defined as a drop of *4% in SpO2 and/or to
<92% after having performed a 1-minute sit-to-stand test.

Exclusion Criteria

- Inability to understand and sign the written consent form
- Inability to perform saturation measurements or sit-to-stand test
- Not willing to be admitted to hospital
- On the discretion of the recruiting clinician if he or she deems a patient
not eligible
- Contra-indication for dexamethasone
- History of gastrointestinal bleeding

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome will be time to first hospital admission. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary outcomes are time to self-reported recovery, COVID-19 severity and<br /><br>self-reported disease burden. </p><br>